Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

Zoeller, JJ; Vagodny, A; Daniels, VW; Taneja, K; Tan, BY; DeRose, YS; Fujita, M; Welm, AL; Letai, A; Leverson, JD; Blot, V; Bronson, RT; Dillon, DA; Brugge, JS

Brugge, JS (corresponding author), Harvard Med Sch, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.; Brugge, JS (corresponding author), Harvard Med Sch, Ludwig Ctr Harvard, 240 Longwood Ave, Boston, MA 02115 USA.

BREAST CANCER RESEARCH, 2020; 22 (1):

Abstract

Background Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索